文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症监护病房急性肾损伤患者中心静脉压轨迹与28天死亡风险的关联

[Association between central venous pressure trajectories and 28-day mortality risk in ICU patients with acute kidney injury].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2026-01-01
一句话结论ICU急性肾损伤患者48小时内中心静脉压轨迹与28天死亡风险相关,高初始水平并先升后降组死亡风险是低水平组的2.02倍。

该回顾性队列研究纳入2021年1月至2024年12月贵州医科大学附属医院急诊及综合ICU诊断急性肾损伤后48小时内的409例患者,基于每2小时测量的中心静脉压采用组轨迹模型识别出4种轨迹。高初始水平并先升后降组(41例,10.0%)28天累积生存率最低,校正混杂后28天死亡风险高于低水平组(HR=2.02,95%CI 1.15-3.55,P=0.014)。限制性立方样条显示48小时内中心静脉压平均值与28天死亡率呈线性正相关,当≥11.33 mmHg时死亡风险随中心静脉压升高而逐渐增加。

要点

  • 高初始中心静脉压并先升后降组28天死亡风险较低水平组升高(HR=2.02,95%CI 1.15-3.55,P=0.014)。
  • 48小时内中心静脉压平均值与28天死亡率呈线性正相关,≥11.33 mmHg时死亡风险随中心静脉压升高而逐渐增加。
  • 中心静脉压≥11.33 mmHg组28天累积生存率低于<11.33 mmHg组(Log-rank χ²=4.658,P=0.031)。
  • 男性、低血压或使用血管活性药物的急性肾损伤患者中,中心静脉压平均值与28天死亡率的线性正相关仍存在(均P<0.05)。
  • 高初始水平组入院血氧饱和度和血钠最低,院内死亡率、血液净化治疗和侵入性机械通气比例最高。

适用人群与场景

  • 2021年1月至2024年12月贵州医科大学附属医院急诊及综合ICU诊断急性肾损伤后48小时内入院的患者。
  • 共纳入409例急性肾损伤患者。

诊断标准与关键阈值

  • 采用组轨迹模型基于入院48小时内每2小时测量的中心静脉压识别出4种轨迹:低水平组98例(24.0%)、中等水平组168例(41.1%)、中高水平组102例(24.9%)、高水平组41例(10.0%)。
  • 限制性立方样条显示中心静脉压平均值≥11.33 mmHg(1 mmHg=0.133 kPa)时死亡风险随中心静脉压升高而逐渐增加。

研究设计与关键结果

  • 回顾性队列研究,纳入409例ICU急性肾损伤患者,采用组轨迹模型识别中心静脉压轨迹。
  • 四组间性别、年龄、体温、脉搏、呼吸频率、收缩压及合并症无显著差异;高水平组入院血氧饱和度和血钠最低,院内死亡率、血液净化治疗和侵入性机械通气比例最高;低水平组ICU住院时间最短。
  • Kaplan-Meier曲线显示四组28天累积生存率差异有统计学意义(Log-rank χ²=9.258,P=0.026),高水平组28天累积生存率最低。
  • 多因素Cox回归校正性别、年龄、合并症、入院生命体征及检验结果后,高水平组28天死亡风险高于低水平组(HR=2.02,95%CI 1.15-3.55,P=0.014)。
  • 限制性立方样条显示48小时内每2小时监测的中心静脉压平均值与28天死亡率呈线性正相关,≥11.33 mmHg时死亡风险随中心静脉压升高而逐渐增加。
  • 中心静脉压≥11.33 mmHg组28天累积生存率低于<11.33 mmHg组(Log-rank χ²=4.658,P=0.031)。
  • 亚组分析显示,男性、低血压或使用血管活性药物的急性肾损伤患者中,中心静脉压平均值与28天死亡率的线性正相关仍存在(均P<0.05)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,动态监测中心静脉压可有效识别预后不良的高危急性肾损伤患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the relationship between the trajectory of central venous pressure (CVP) changes and the 28-day mortality risk in patients with acute kidney injury (AKI) in the intensive care unit (ICU).

METHODS: A retrospective cohort study was conducted. Patients admitted to the emergency department and general ICU of the Affiliated Hospital of Guizhou Medical University within 48 hours of diagnosis with AKI from January 2021 to December 2024 were enrolled. The CVP values measured every 2 hours within 48 hours of admission were collected. The group-based trajectory model (GBTM) was used to identify research subjects with similar CVP development trajectories within the group and they were assigned to specific CVP trajectory groups. The difference in 28-day cumulative survival rate of patients in different CVP trajectory groups was compared using the Kaplan-Meier survival curve, and the impact of CVP trajectory on 28-day mortality risk was evaluated using multivariate Cox proportional hazards regression analysis. The dose-response relationship between CVP average value and 28-day mortality risk in AKI patients was analyzed using the restricted cubic spline (RCS) method. Subgroup analysis was conducted based on age, gender, comorbidities, and treatment interventions to evaluate the prognostic effect of CVP on different patient subgroups.

RESULTS: A total of 409 patients with AKI were included. Four CVP trajectories were identified using GBTM analysis, namely: the initial CVP level was low and gradually increased (low level group, 98 cases, accounting for 24.0%); the initial CVP level was moderate and gradually increased (moderate level group, 168 cases, accounting for 41.1%); the initial CVP level was between moderate and high and gradually increased (medium-high level group, 102 cases, accounting for 24.9%); the initial CVP level was high and gradually increased before gradually decreasing (high level group, 41 cases, accounting for 10.0%). There were no significant differences in gender, age, body temperature, pulse, respiratory rate, systolic blood pressure, and comorbidities among the four groups. However, the admission blood oxygen saturation and blood sodium were the lowest in the high-level group, and the in-hospital mortality, the proportions of blood purification treatment and invasive mechanical ventilation were the highest in this group. The length of ICU stay was the shortest in the low-level group. The Kaplan-Meier survival curve showed that there was a statistically significant difference in the 28-day cumulative survival rate among the four CVP trajectory groups (Log-rank test: χ 2=9.258, P=0.026), and the 28-day cumulative survival rate of the high-level group was the lowest. Multivariate Cox proportional hazards regression analysis showed that, after adjusting for gender, age, comorbidities, admission vital signs, and test results, the 28-day mortality risk of the high-level group was higher than that of the low-level group [hazard ratio (HR)=2.02, 95% confidence interval (95%CI) was 1.15-3.55, P=0.014]. The RCS curve indicated that the average value of CVP monitoring at intervals of 2 hours within 48 hours after admission was linearly positively correlated with the 28-day mortality of patients. When CVP≥11.33 mmHg (1 mmHg=0.133 kPa), the mortality risk gradually increased with the increase in CVP. The Kaplan-Meier survival curve showed that the 28-day cumulative survival rate of patients in the CVP≥11.33 mmHg group was lower than that in the CVP<11.33 mmHg group (Log-rank test: χ 2=4.658, P=0.031). Subgroup analysis showed that the linear positive correlation between the CVP average value and the 28-day mortality still existed in AKI patients who were male, hypotensive, or using vasoactive drugs (all P<0.05).

CONCLUSIONS: The trajectory of CVP changes in AKI patients in the ICU is closely related to the 28-day mortality risk. Dynamic monitoring of CVP can effectively identify high-risk patients with poor prognosis.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Lan S, Deng S, Huang R, et al. [Association between central venous pressure trajectories and 28-day mortality risk in ICU patients with acute kidney injury]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 42281541. doi:10.3760/cma.j.cn121430-20250929-00499

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。